News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Oct 29, 2024
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK’s AREXVYJun 18, 2024
Clover Announces Positive Preliminary PhaseⅠResults for Bivalent RSV Vaccine Candidate SCB-1019 in Older AdultsApr 08, 2024
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult CohortDec 29, 2023
Clover Announces Positive PhaseⅠResults for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)Dec 13, 2023
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine CandidateNov 07, 2023
Clover Completes BLA Submission for Seasonal Influenza Vaccine in BrazilSep 12, 2023
Clover Launches Quadrivalent Seasonal Influenza Vaccine in Mainland ChinaJul 11, 2023
Clover Provides Updates on Business and R&D Pipeline DevelopmentMay 24, 2023
Clover Expands Sales and Distribution Network for Upcoming Quadrivalent Seasonal Influenza Vaccine Launch in ChinaMar 29, 2023
Clover Announces Corporate Updates and Full Year 2022 Financial Results
